Safety Study of IL-7 in HIV-infected Patients (Inspire)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

July 31, 2010

Conditions
HIV InfectionsLymphopenia
Interventions
DRUG

CYT 107

3 dose levels: 3, 10 and 20µg/kg/week.3administrations

Trial Locations (8)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

33136

University of Miami School of Medicine, Miami

44106-2602

Case Western Reserve University, Cleveland

Unknown

McGill University Health Center (MUHC), Montreal

Hopital Henri Mendor-Service d'Immunologie Clinique, Créteil

Hopital Kremlin Bicêtre, Le Kremlin-Bicêtre

Hopital Saint Louis, Paris

San Raffaele Scientific Institute, Milan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cytheris SA

INDUSTRY

NCT00477321 - Safety Study of IL-7 in HIV-infected Patients (Inspire) | Biotech Hunter | Biotech Hunter